ICON plc

PreveCeutical Awards ICON Analgesic Program (Painkiller) Clinical Development

Retrieved on: 
Tuesday, February 7, 2023
Investigator's brochure, IND, FSE, ICON plc, CSE, Client, ICON, CTA, Biotechnology, Government, Cros, Fine chemical, Pharmaceutical industry

Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that on February 1, 2023, PreveCeutical has appointed ICON as the clinical research organization (CRO) to complete the following.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that on February 1, 2023, PreveCeutical has appointed ICON as the clinical research organization (CRO) to complete the following.
  • Construction of a clinical development plan for Phase 1 through pivotal Phase 3 studies.
  • PreveCeutical shall commence the clinical development with ICON in Q1 2023 and work with regulators to seek any potential fast track provisions as we believe that a non-addictive pain analgesic will meet the requirements due to the global abuse of painkillers currently available.
  • PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "Moving forward as PreveCeutical transitions from an R&D company into clinical development, it is our priority to select the best partner for this development.

ICON Issues Financial Guidance for Full Year 2023

Retrieved on: 
Tuesday, January 10, 2023
Professional Services, Finance, Public expenditure, Growth, ICON plc, Environment, ICLR, Share repurchase, Pharmaceutical industry

ICON plc , (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2023.

Key Points: 
  • ICON plc , (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2023.
  • Our outlook for 2023 reflects a continued solid demand environment albeit with persistent macroeconomic challenges, resulting in full year revenue guidance in the range of $7,940 - $8,340 million and adjusted earnings per share1 guidance in the range of $12.40 - $13.05.”
    Full year 2023 financial guidance assumptions:
    Circa $1.1 billion of free cash flow and capital expenditures of circa $200 million.
  • Excludes any potential share repurchase or M&A activity in the above guidance.
  • With respect to full year 2022, the company reaffirmed its current guidance of revenue in the range of $7,690 - $7,810 million and adjusted earnings per share1 in the range of $11.65 - $11.85.

Global Traumatic Brain Injury Assessment and Management Devices Market to Grow by $1.73 Billion During 2023-2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023
Medical Devices, Health, ICON, ICON plc, Siemens, Research, English v. General Electric Co., Canon Inc., Boston Scientific, Medical imaging, Retail

This study identifies the growing neurology specialty hospitals and clinics as one of the prime reasons driving the traumatic brain injury assessment and management devices market growth during the next few years.

Key Points: 
  • This study identifies the growing neurology specialty hospitals and clinics as one of the prime reasons driving the traumatic brain injury assessment and management devices market growth during the next few years.
  • Also, the use of pressure monitors reveals a lucrative growth opportunity and increasing initiatives and support from governments and healthcare organizations will lead to sizable demand in the market.
  • The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
  • The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

ICON plc to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 3, 2023
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Clinical Trials, Conference, ICLR, ICON plc, Pharmaceutical industry, ICON

ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 5:15pm PST/ 8.15pm EST.

Key Points: 

ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 5:15pm PST/ 8.15pm EST.

Global Traumatic Brain Injury Assessment and Management Devices Market 2023-2027

Retrieved on: 
Wednesday, January 4, 2023
Canon Inc., ICON, English v. General Electric Co., Boston Scientific, ICON plc, Research, Siemens, Medical imaging, Retail

This study identifies the growing neurology specialty hospitals and clinics as one of the prime reasons driving the traumatic brain injury assessment and management devices market growth during the next few years.

Key Points: 
  • This study identifies the growing neurology specialty hospitals and clinics as one of the prime reasons driving the traumatic brain injury assessment and management devices market growth during the next few years.
  • The analyst presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
  • Our report on the traumatic brain injury assessment and management devices market covers the following areas:
    This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading traumatic brain injury assessment and management devices market vendors that include Advanced Brain Monitoring Inc., Boston Scientific Corp., BrainScope Co. Inc., Canon Inc., Compumedics Ltd., Elekta AB, Esaote Spa, General Electric Co., ICON plc, InfraScan Inc., Integra Lifesciences Holdings Corp., Koninklijke Philips NV, NanoDx Inc., Natus Medical Inc., Nihon Kohden Corp., NovaSignal Corp., Oculogica, RAUMEDIC AG, Siemens AG, and Vivonics Inc. Also, the traumatic brain injury assessment and management devices market analysis report includes information on upcoming trends and challenges that will influence market growth.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

The healthcare analytical testing services market is projected to reach USD 11.1 billion by 2027 from USD 6.5 billion in 2022, at a CAGR of 11.4%

Retrieved on: 
Thursday, December 22, 2022
INC, USD, Charles River Laboratories, Pulse, Cros, Intertek, Cinven, Immunogenicity, Drug development, Growth, Sartorius AG, Safety, ICON plc, Steris, LabCorp, Environmental monitoring, SGS, Pressure, Therapy, Parexel, Merck Group, Wuxi, Eurofins Scientific, Fine chemical, Vaccine, Medical device

View original content:https://www.prnewswire.com/news-releases/the-healthcare-analytical-testi...

Key Points: 
  • The healthcare analytical testing services market is projected to reach USD 11.1 billion by 2027 from USD 6.5 billion in 2022, at a CAGR of 11.4%.
  • • Service Development/Innovation: Detailed insights on the upcoming trend, and service launches in the global healthcare analytical testing services market.
  • • Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the global healthcare analytical testing services market.
  • • Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and services of leading players in the global healthcare analytical testing services market.

ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, Insight, Medidata Solutions, Biotechnology, Perception, Clinical trial, Poster, ICON plc, Sales promotion, Partnership, Knowledge, Digital, Intelligence, Medicine, Government, Marketing, Vserv Digital Services, ICLR, Gold, Laupāhoehoe Community Public Charter School, Print, SME One Asia Awards, Creative, Data, Professional, Diversity, Pharmaceutical industry, Evidence, ICON

The awards include the Best Contract Research Organisation Full-Service Providers from Scrip, marking the second consecutive time after a win in 2021.

Key Points: 
  • The awards include the Best Contract Research Organisation Full-Service Providers from Scrip, marking the second consecutive time after a win in 2021.
  • ICONs innovation capabilities were recognised as the company won the Data Analytics/Business Intelligence category in the Fierce Biotech Innovation Awards Life Sciences 2022.
  • In November, ICON was recognised in the Financial Times European Leader in Diversity 2023 Award List, ranked 80th out of 850 companies.
  • With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 113 locations in 53 countries as at September 30, 2022.

Home Health: Best Practices and Processes to Build Confidence in the Value of In-Home Services, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, November 30, 2022
Value, Family, ICON, Communication, Food, Caregiver, Patient, Clinical trial, ICON plc, Medical imaging, Medicine, Online shopping

TORONTO, Nov. 30, 2022 /PRNewswire-PRWeb/ -- In-home services are proving to be of true value in clinical research, improving patient recruitment by reducing patient burden and reaching more diverse patient populations. While looking to the future of clinical trials and shifting the paradigm to make them more patient-centric and efficient, home health and home-based services promise to be an important component in delivering on this mission.

Key Points: 
  • The speaker will also share insights on measuring success through metrics such as patient retention and recruitment and diversity and inclusion.
  • Register to learn the best practices and processes to build confidence in the value of home health services.
  • For more information, or to register for this event, visit Home Health: Best Practices and Processes to Build Confidence in the Value of In-Home Services .
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

T-Heart Appoints Sarah Sorrel as Independent Board Member

Retrieved on: 
Tuesday, November 29, 2022
Cardiology, Biotechnology, Surgery, General Health, Health, Medical Devices, Hospitals, Clinical Trials, Tricuspid valve, ICON, Association of British HealthTech Industries, ICON plc, Multimedia, Yale University, Female, Acquisition, Knowledge, Medtech, Patient, Human, Heart failure, EFS, European, Adrenal insufficiency, Death, Applied science, Quality of life, Science, FDA, Pharmaceutical industry, Medical imaging, Engineering

T-Heart, a medtech company developing a truly novel and differentiated transcatheter tricuspid prosthetic heart valve specifically designed for tricuspid regurgitation, today announced it has appointed Sarah Sorrel as its first independent member of the Board of Directors.

Key Points: 
  • T-Heart, a medtech company developing a truly novel and differentiated transcatheter tricuspid prosthetic heart valve specifically designed for tricuspid regurgitation, today announced it has appointed Sarah Sorrel as its first independent member of the Board of Directors.
  • Sarah Sorrel joins the T-Heart Board of Directors when the company is preparing its First in Human / Early Feasibility Study, bringing a valuable experience and expertise to its execution.
  • Soad El Ghazouani, CEO of T-Heart said: We are excited to have an independent board member with such considerable experience in medtech, and more specifically in the transcatheter heart valve field, joining the board at T-Heart at a key moment for the company.
  • Ms. Sorrel is the third female out of five representatives to join the board of T-Heart.

BetterInvesting™ Magazine Update on Icon PLC and Williams-Sonoma Inc.

Retrieved on: 
Monday, November 28, 2022
Steps, WSM, National Association, Undervalued stock, NAIC, Education, ICON plc, Committee, NYSE, Volunteering, ICLR, Williams-Sonoma, Inc., CFA, Security (finance)

Learn more including 6 Steps for Successful Stock Investing at: https://www.betterinvesting.org/learn-about-investing/investor-education...

Key Points: 
  • Learn more including 6 Steps for Successful Stock Investing at: https://www.betterinvesting.org/learn-about-investing/investor-education...
    Check the January-February 2023 issue of BetterInvesting Magazine for more details about the latest stocks.
  • Non-members can utilize the limited, trial version of the BetterInvesting online stock selection and analysis tools to study the investment potential of Icon PLC and Williams-Sonoma Inc. by viewing their fundamental data and applying judgments.
  • As stated, the BetterInvesting committee's Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors.
  • BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases.